Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.

Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI.

Eur Psychiatry. 2012 Oct;27(7):518-21. doi: 10.1016/j.eurpsy.2011.03.006. Epub 2011 Jun 12.

PMID:
21665441
[PubMed - indexed for MEDLINE]
2.

Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.

Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI.

J Affect Disord. 2012 Feb;136(3):1174-8. doi: 10.1016/j.jad.2011.04.059. Epub 2011 Sep 10.

PMID:
21911258
[PubMed - indexed for MEDLINE]
3.

S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.

Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M.

Am J Psychiatry. 2010 Aug;167(8):942-8. doi: 10.1176/appi.ajp.2009.09081198. Epub 2010 Jul 1.

PMID:
20595412
[PubMed - indexed for MEDLINE]
4.

Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.

Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Abarca JE, Herrera-Guzmán D, Montelongo-Pedraza P, Padrós Blázquez F, Peró-Cebollero M, Guàrdia-Olmos J.

J Affect Disord. 2010 Jun;123(1-3):341-50. doi: 10.1016/j.jad.2009.10.009. Epub 2009 Nov 6.

PMID:
19896719
[PubMed - indexed for MEDLINE]
5.

SAMe and sexual functioning.

Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI.

Eur Psychiatry. 2012 Aug;27(6):451-4. doi: 10.1016/j.eurpsy.2011.01.003. Epub 2011 Mar 12.

PMID:
21398094
[PubMed - indexed for MEDLINE]
6.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
[PubMed - indexed for MEDLINE]
7.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.

J Psychiatr Res. 2005 Jan;39(1):43-53.

PMID:
15504423
[PubMed - indexed for MEDLINE]
8.

Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.

Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI.

J Clin Psychiatry. 2012 Jun;73(6):843-8. doi: 10.4088/JCP.11m07139. Epub 2012 May 15.

PMID:
22687580
[PubMed - indexed for MEDLINE]
9.

Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.

Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, Guàrdia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE.

J Psychiatr Res. 2009 Jun;43(9):855-63. doi: 10.1016/j.jpsychires.2008.10.015. Epub 2009 Jan 6.

PMID:
19128810
[PubMed - indexed for MEDLINE]
11.

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.

Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC.

J Affect Disord. 2011 Oct;133(3):467-76. doi: 10.1016/j.jad.2011.04.032. Epub 2011 May 23.

PMID:
21601287
[PubMed - indexed for MEDLINE]
12.

Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.

Ferguson JM, Wesnes KA, Schwartz GE.

Int Clin Psychopharmacol. 2003 Jan;18(1):9-14.

PMID:
12490769
[PubMed - indexed for MEDLINE]
13.

A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W, Bae S, Renshaw PF.

Am J Psychiatry. 2012 Sep;169(9):937-45. doi: 10.1176/appi.ajp.2012.12010009.

PMID:
22864465
[PubMed - indexed for MEDLINE]
14.

Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.

Herrera-Guzmán I, Herrera-Abarca JE, Gudayol-Ferré E, Herrera-Guzmán D, Gómez-Carbajal L, Peña-Olvira M, Villuendas-González E, Joan GO.

Psychiatry Res. 2010 May 30;177(3):323-9. doi: 10.1016/j.psychres.2010.03.006. Epub 2010 Apr 10.

PMID:
20385412
[PubMed - indexed for MEDLINE]
15.

Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.

Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X.

J Clin Psychiatry. 2008 Aug;69(8):1228-336.

PMID:
18681749
[PubMed - indexed for MEDLINE]
16.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

PMID:
18462573
[PubMed - indexed for MEDLINE]
Free Article
17.

Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.

Yang H, Chuzi S, Sinicropi-Yao L, Johnson D, Chen Y, Clain A, Baer L, McGrath PJ, Stewart JW, Fava M, Papakostas GI.

Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):145-50. doi: 10.1007/s00406-009-0031-3. Epub 2009 Jul 2.

PMID:
19572158
[PubMed - indexed for MEDLINE]
18.

Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study.

Hinkelmann K, Moritz S, Botzenhardt J, Muhtz C, Wiedemann K, Kellner M, Otte C.

Psychoneuroendocrinology. 2012 May;37(5):685-92. doi: 10.1016/j.psyneuen.2011.08.012. Epub 2011 Sep 23.

PMID:
21944955
[PubMed - indexed for MEDLINE]
19.

Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial.

Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng LJ, Stecher VJ.

J Clin Psychiatry. 2006 Feb;67(2):240-6.

PMID:
16566619
[PubMed - indexed for MEDLINE]
20.

A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.

Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI.

J Clin Psychiatry. 2006 Nov;67(11):1754-9.

PMID:
17196056
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk